Juliet Tammenoms Bakker
Co-Founder and Managing Director @ Longitude Capital
New York, United States
Juliet Tammenoms Bakker is a Series C investor at Longitude Capital in New York focused on Medical Device and Health Care. Ms. Bakker is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Ms. Bakker was a Managing Director of Pequot Ventures where she founded the life sciences investment practice. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International. Previously, she was asell-side equity analyst with Banque Paribas. Ms. Bakker began her career as an investment banker in the corporate finance department at PaineWebber. She currently serves on the boards of Alphaeon, Axonics Modulation Technologies, Encore Dermatology, Nalu, RxSight and Venus Concept. She has previously served on the boards of Ablation Frontiers (acquired by Medtronic), AqueSys (acquired by Allergan), CryoVascular Systems (acquired by Boston Scientific), Embolic Protection (acquired by Boston Scientific), Enteric Medical (acquired by Boston Scientific), eyeonics (acquired by Bausch+Lomb), Genyx Medical (acquired by C.R.Bard), Insulet (PODD), Precision Dermatology (acquired by Valeant Pharmaceuticals), and Sadra Medical (acquired by Boston Scientific). Ms. Bakker holds an M.P.A. from the John F. Kennedy School of Government at Harvard University and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University (“CALS”), where she is a member of the CALS Advisory Council. Ms. Bakker is also a board member of the Boys and Girls Club of Greenwich.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 54%
Last updated:
For AI agents: llms.txt
Industries Juliet Tammenoms Bakker invests in
Stages Juliet Tammenoms Bakker invests in
Countries Juliet Tammenoms Bakker invests in
Investment Focus
Industry
- Medical Device 9 (69%)
- Health Care 6 (46%)
- Biotechnology 2 (15%)
- Health Diagnostics 2 (15%)
- Audio 1 (8%)
Stage
- Series C 5 (38%)
- Series B 2 (15%)
- Funding Round 2 (15%)
- Series A 1 (8%)
- Series D 1 (8%)
Country
- United States 8 (62%)
- Canada 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Endogenex
|
Endogenex develops an endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels. Established in 2017, Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D. | $88M / Series C / Jun 25, 2024 | |
Ceribell
|
Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective.The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision making. The Ceribell EEG System can be setup by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications. | $53M / Series C / Apr 29, 2021 | |
Eargo
|
Eargo is a medical device startup company that produces hearing aids that allow customers to access help for their hearing loss.The company also offers online hearing screenings and virtual support, so customers don’t need to have an in-person visit. It offers a rechargeable hearing aids that can be controlled with a smartphone. Its innovativeproduct and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from licensed hearing professionals via phone, text, email, or video chat. The Eargo solution is offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels. | $81.6M / Series E / Jul 29, 2020 | |
Axonics Modulation Technologies
|
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder. | $40M / Series C / Apr 03, 2018 | |
Alphaeon
|
Alphaeon is a social commerce company with the goal of transforming self-pay healthcare by bringing to market highly innovative products and services to promote consumer wellness, beauty, and performance. The company works in partnership with board-certified physicians ensuring access to leading advancements in lifestyle healthcare. The companywas founded Robert E. Grant in 2013 and is based in Irvine, California. | $53.7M / Convertible Note / Aug 10, 2016 | |
|
Alphaeon
|
Alphaeon is a social commerce company with the goal of transforming self-pay healthcare by bringing to market highly innovative products and services to promote consumer wellness, beauty, and performance. The company works in partnership with board-certified physicians ensuring access to leading advancements in lifestyle healthcare. The companywas founded Robert E. Grant in 2013 and is based in Irvine, California. | $80.1M / Series B / Nov 20, 2015 | |
RxSight
|
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL®), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens(IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. | $52M / Jun 04, 2015 | |
AqueSys
|
The Innovation Factory acquires novel medical technology ideas from individual inventors, corporations and universities, develops ideas comprehensively from proof of concept to FDA approval into marketable products, and then launches businesses around those products. We manage the complex path to market for early-stage medical device companies.With our deeply experienced management team and top-tier funding partners, we have assembled the intellectual, scientific, operational and financial resources needed to take a great idea from paper to production. Our nimble approach to both product and business development allows us to vet ideas properly and efficiently, maximizing predictability and speeding time-to-market while reducing risk for everyone involved.The Innovation Factory welcomes medical-related ideas and referrals from a variety of sources, and we promise confidentiality and timely response to all inquiries. For more information, please select the appropriate perspective: Inventor, University or Corporation. | $43.6M / Series D / Jan 16, 2014 | |
|
AqueSys
|
The Innovation Factory acquires novel medical technology ideas from individual inventors, corporations and universities, develops ideas comprehensively from proof of concept to FDA approval into marketable products, and then launches businesses around those products. We manage the complex path to market for early-stage medical device companies.With our deeply experienced management team and top-tier funding partners, we have assembled the intellectual, scientific, operational and financial resources needed to take a great idea from paper to production. Our nimble approach to both product and business development allows us to vet ideas properly and efficiently, maximizing predictability and speeding time-to-market while reducing risk for everyone involved.The Innovation Factory welcomes medical-related ideas and referrals from a variety of sources, and we promise confidentiality and timely response to all inquiries. For more information, please select the appropriate perspective: Inventor, University or Corporation. | $35M / Series C / Jun 02, 2010 | |
Sadra Medical
|
Sadra Medical is exploring new minimally invasive alternatives to traditional surgical valve replacement. The company hopes that devices allowing such procedural advances will facilitate and enhance treatment of aortic valve disease.Sadra Medical is dedicated to developing innovative new therapies for the treatment of aortic valve disease. Bydeveloping minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients. Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in U.S. have aortic valve stenosis; however, only a small percentage of those are treated with the current standard of care, valve replacement during open-heart surgery using cardiopulmonary bypass. By developing a highly effective aortic valve replacement that is designed to reduce the risks and morbidity associated with open surgical valve replacement, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today.Sadra Medical, a subsidiary of Boston Scientific. | Series C / May 22, 2009 | |
| See all 13 investments → | |||
Co-Investors
About Longitude Capital
Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance the quality of life, and/or reduce system costs. They invest in both privately held and publicly traded life science companies through a variety of investment approaches. Since2006, Longitude Capital has raised over $1.2 billion across three funds and demonstrated an ability to source, manage and exit attractive investments across multiple market cycles.Their venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile, and attractive expected returns within three to five years from the initial investment.Longitude Capital seeks to identify new investment opportunities by tapping into their broad network of industry relationships or through the execution of intensive thematic research into emerging therapeutic areas or industry sub-sectors. They utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity and equity-linked instruments.
Longitude Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amar Patel
Associate
|
|||
Brian Liu
Principal; Vice President
|
|||
David Hirsch
Managing Director
|
|||
|
Juliet Tammenoms Bakker
Co-Founder and Managing Director
|
|||
Karthik Bolisetty
Associate
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Juliet Tammenoms Bakker invest in?
Juliet Tammenoms Bakker invests primarily in Medical Device, Health Care and Biotechnology startups, most often at Series C and Series B stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Juliet Tammenoms Bakker last invest?
The most recent investment recorded for Juliet Tammenoms Bakker closed in Jun 2024. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
